Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775110 · ClinicalTrials.gov registry record · Phase 4
Natalizumab Temporary Discontinuation Study
A Phase 4 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT02775110 is a Phase 4 study that has completed, run by University at Buffalo. The registered enrollment target is 50 participants.
The verdict
NCT02775110, a Phase 4 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study evaluates the discontinuation of natalizumab either immediately or tapered off in the treatment of multiple sclerosis. Half of the fifty (50) participants will discontinue natalizumab immediately and the other half will taper off the drug, having two additional infusions, one at six weeks- and one at eight weeks-post discontinuation.
Interventions
- OTHER Natalizumab discontinuation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02775110
The ClinicalTrials.gov registry entry for NCT02775110 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Natalizumab discontinuation is the first listed.
NCT02775110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02775110 about?
NCT02775110 is a clinical study titled "Natalizumab Temporary Discontinuation Study". This study evaluates the discontinuation of natalizumab either immediately or tapered off in the treatment of multiple sclerosis. Half of the fifty (50) participants will discontinue natalizumab immediately and the other half will taper off the drug, having two additional infusions, one at six weeks...
What is the current status of trial NCT02775110?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2012-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02775110?
The interventions under investigation include: Natalizumab discontinuation (OTHER).
Who is sponsoring clinical trial NCT02775110?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.